Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Baxter
Colorcon
McKinsey

Last Updated: September 28, 2022

CLINICAL TRIALS PROFILE FOR GOLIMUMAB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for golimumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00207714 ↗ An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis Completed Centocor BV Phase 2 2003-11-01 Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.
NCT00207714 ↗ An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis Completed Centocor, Inc. Phase 2 2003-11-01 Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.
NCT00207740 ↗ A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma Completed Centocor BV Phase 2 2004-08-01 The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
NCT00207740 ↗ A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma Completed Centocor, Inc. Phase 2 2004-08-01 The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for golimumab

Condition Name

Condition Name for golimumab
Intervention Trials
Rheumatoid Arthritis 18
Ulcerative Colitis 9
Colitis, Ulcerative 8
Psoriatic Arthritis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for golimumab
Intervention Trials
Arthritis 30
Arthritis, Rheumatoid 22
Colitis 19
Colitis, Ulcerative 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for golimumab

Trials by Country

Trials by Country for golimumab
Location Trials
United States 284
Canada 43
Germany 18
Poland 13
Belgium 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for golimumab
Location Trials
California 17
Texas 17
North Carolina 15
New York 15
Pennsylvania 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for golimumab

Clinical Trial Phase

Clinical Trial Phase for golimumab
Clinical Trial Phase Trials
Phase 4 20
Phase 3 26
Phase 2/Phase 3 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for golimumab
Clinical Trial Phase Trials
Completed 37
Recruiting 12
Not yet recruiting 9
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for golimumab

Sponsor Name

Sponsor Name for golimumab
Sponsor Trials
Centocor, Inc. 13
Janssen Research & Development, LLC 12
Merck Sharp & Dohme Corp. 11
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for golimumab
Sponsor Trials
Industry 62
Other 48
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Johnson and Johnson
Mallinckrodt
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.